Anonymous25 days ago
Hims & Hers Health and Novo Nordisk have reached a landmark partnership agreement that ends their bitter legal dispute over compounded weight-loss drugs, sending HIMS stock surging more than 40%. Under the deal, Hims will sell FDA-approved Wegovy and Ozempic on its telehealth platform while ceasing to advertise compounded GLP-1 products — a pivotal shift in the rapidly evolving, $100-billion weight-loss drug market that raises fundamental questions about drug pricing, patient access, and the future of telehealth.